Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer wins Ireland court case for Lipitor patent

Pfizer wins Ireland court case for Lipitor patent

17th July 2007

Pfizer has announced that a high court in Dublin, Ireland has ruled in its favour in a patent case relating to atorvastatin, the active ingredient in its cholesterol-lowering drug Lipitor (atorvastatin calcium).

The court ruled that a product from generic pharmaceuticals manufacturer Ranbaxy aiming to compete with the drug would infringe the patent of Lipitor, with the court ruling to prevent the firm from launching its compound before the basic Irish patent on Lipitor expires in November 2011.

Pfizer notes that this decision is subject to a possible appeal from Ranbaxy.

Allen Waxman, general counsel of Pfizer, described the decision of the court as an additional confirmation of the validity of its patents and intellectual property rights regarding Lipitor.

“It also is an important outcome for Pfizer and other medical innovators who invest in high-risk research to develop life-saving medicines and for the patients who benefit from those medicines.”

Last month, Pfizer reported the results of the stroke prevention by aggressive reduction in cholesterol levels (Sparcl) trial of patients with type two diabetes who have experienced a stroke or mini stroke who have no previous history of coronary heart disease.

The company reported that patients administered with Lipitor exhibited a 30 per cent reduction in stroke, with a 51 per cent drop in the risk of developing coronary heart disease or major coronary events compared to individuals receiving placebo.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.